Trials / Completed
CompletedNCT04170998
Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 283 (actual)
- Sponsor
- Dong-A ST Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Evogliptin 5mg | Participants receive Evogliptin 5mg orally once a day |
| DRUG | Evogliptin Placebo | Participants receive placebo to match Evogliptin 5mg orally once a day |
| DRUG | Dapagliflozin 10mg | Participants receive Dapagliflozin orally once a day |
| DRUG | Metformin ≥ 1000mg | Metformin are administered at the same dose and formulation. |
Timeline
- Start date
- 2020-01-02
- Primary completion
- 2021-06-28
- Completion
- 2021-12-08
- First posted
- 2019-11-20
- Last updated
- 2021-12-10
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04170998. Inclusion in this directory is not an endorsement.